Toxoplasma gondii infection reactivation predominantly occurs among patients after allogeneic haematopoietic stem cell transplantation. Mostly, reactivation occurs during first 3 months after transplant, especially when risk factors are present. We report a case of late cerebral toxoplasmosis reactivation, which was probably triggered by a brief course of corticosteroids, administered for chronic graft-versus-host disease (cGVHD). In the presence of risk factors, such as cGVHD, prophylactic treatment for toxoplasmosis should be reinstituted; Trimethoprim-sulfamethoxasole most probably prevented earlier reactivation of toxoplasmosis in our patient. Keywords: cerebral toxoplasmosis; late reactivation; prophylaxis Toxoplasma gondii encephalitis is a well-recognised opportunistic infection in haematologic patients after allogeneic haematopoietic stem cell transplantation (allo-HSCT). Besides encephalitis, other common presentations of toxoplasmosis are pneumonitis and myocarditis.
Toxoplasma gondii encephalitis is a well-recognised opportunistic infection in haematologic patients after allogeneic haematopoietic stem cell transplantation (allo-HSCT). Besides encephalitis, other common presentations of toxoplasmosis are pneumonitis and myocarditis. 1 Most cases of post-transplant toxoplasmosis occur as a consequence of reactivation of latent infection. T. gondii is endemic in Slovenia, 75% of the population being seropositive. 2 Aside from a positive serostatus prior to transplantation, severe graft-versus-host disease (GVHD) is also a well-known risk factor for Toxoplasma reactivation in allo-HSCT recipients. 3 Toxoplasmosis generally develops within the first 6 months after transplantation with the highest incidence in the second and third months. 3, 4 In the literature, we have found only two cases that occurred more than 6 months post-transplant. 5, 6 We report a case of late reactivation of cerebral toxoplasmosis that occurred 11 months after allo-HSCT in a patient with chronic myeloid leukaemia (CML).
Case report
A 42-year-old woman with CML underwent allo-HSCT from her HLA-identical brother. Prior to the procedure, T. gondii antibodies were not assessed in either the donor or the recipient. The conditioning regimen comprised TBI (1200 cGy) and cyclophosphamide. Prophylaxis of GVHD was with a short course of methotrexate (MTX), and cyclosporine (CsA) for 6 months. After transplantation, the patient experienced acute grade I GVHD with skin involvement, which resolved after topical steroid treatment. Concomitantly she was given trimethoprim-sulfametoxasole (TMP-SMX) as anti-Pneumocystis carinii prophylaxis for 6 months.
Ten months after allo-HSCT, the patient presented with fever, dry cough and pleuritic chest pain. Signs of skin and gastrointestinal GVHD were absent. Chest radiography and echocardiography showed bilateral pleural effusions with a concomitant minor pericardial effusion. Laboratory tests revealed slightly elevated liver enzymes. Bacterial and virologic investigations were all negative. A diagnosis of chronic GVHD manifested by exudative pleuropericarditis and minor liver involvement was made. The patient began steroids (methylprednisolone 1 mg/kg p.o. once daily), and she was discharged home without residual symptoms. TMP-SMX was not reinstituted at that time.
A few days after discharge, she developed paresis of her right arm, accompanied by a slight headache and speech difficulties. She was readmitted to the Department of Haematology. Examination on readmission revealed centraltype paresis of the right facial nerve, paresis of the right arm and motor aphasia. Cerebral computer tomography (CT) showed a hypodense lesion of undefined nature in the left side of the thalamus (Figure 1 ). Ophthalmological examination disclosed yellowish-white retinal lesions predominantly in the right eye. The results of lumbal puncture were non-specific, showing slightly elevated proteins and absence of leukaemic cells in the cerebrospinal fluid (CSF). Routine microbiological tests for bacterial, viral, fungal and parasitic pathogens in serum and CSF, including serological tests for T. gondii (IgG ELISA and IgM indirect immunofluorescence) carried out twice, were all negative. The polymerase chain reaction (PCR) amplification test was not available in our hospital at that time.
Over the next few days the patient developed a left hemiparesis, hyperalgesia, hypaesthesia, oedema involving the left side of the body, bradycardia and hypotension. The neurological signs and symptoms progressed to the fullblown picture of a right-sided thalamic syndrome. Followup cerebral CT with contrast showed well-defined round hypodense lesions also in the right thalamus. The neuroradiologist and microbiologist ruled out an infectious origin for the thalamic lesions and concluded that the infiltrates were most probably leukaemic.
Based on these data, we started chemotherapy with high doses of cytosine-arabinoside, combined with head irradiation and repeated intrathecal methotrexate and dexamethasone. After a brief improvement, the patient's condition again began to deteriorate rapidly. She developed signs of septic multiple organ failure including progressive brain damage, and she died from respiratory failure 40 days after readmission. Autopsy demonstrated toxoplasmosis, manifesting with typical bilateral hypothalamic pseudocysts; all other organs were uninvolved. We believe that the reactivation of toxoplasmosis in this patient was the consequence of the short course of corticosteroids given for chronic GVHD.
Discussion
T. gondii is endemic in a large part of Europe including Slovenia. Seropositivity in the general population of these regions ranges between 70 and 96%. 1, 4 In patients undergoing allo-HSCT, the status of IgG antibody to T. gondii should be determined prior to the procedure in order to identify those patients who are at risk of developing toxoplasmosis in the post-transplant period. If neurological symptoms occur in a patient with positive pre-transplant serology who experiences severe GVHD requiring intensified immunosuppression, cerebral toxoplasmosis should be considered.
In our patient, toxoplasmosis serology unfortunately was not performed prior to allo-HSCT. Serological tests carried out twice in the post-transplant period after the appearance of neurological signs and symptoms were negative. This was not surprising because Slavin et al 3 were also unable to detect IgM antibodies in the majority of their allo-HSCT patients with reactivation of toxoplasmosis following transplantation, whereas the initial IgG antibody titres of their patients decreased or even became negative after the procedure. We may conclude that no serological test has a major role in the diagnosis of Toxoplasma infection after marrow transplantation.
Besides CT and magnetic resonance imaging (MRI) of the brain, ophthalmological examination also plays a major part in the diagnosis of cerebral toxoplasmosis. Whiteyellowish retinal lesions are suggestive of ocular toxoplasmosis. 7 The diagnosis can be confirmed by PCR analysis of the anterior chamber fluid. 5 Unfortunately we did not initially recognise the retinal lesions in our patient as infectious in origin, which was perhaps crucial in making the correct diagnosis. Instead, we interpreted the retinal lesions in the context of leukaemic central nervous system involvement.
Although Toxoplasma reactivation usually occurs during the first 6 months following allo-HSCT, late reactivations also occur. 5, 6 In our patient, the reactivation of infection observed more than 10 months after allo-HSCT was probably triggered by the brief course of corticosteroids administered for chronic GVHD. At that time the patient was not receiving any other immunosuppressive treatment, nor was TMP-SMX prophylaxis for P. carinii infection being given. Based on our experience, we believe that in the presence of risk factors, especially corticosteroid treatment, prophylactic therapy for toxoplasmosis should also be given. Late outbreaks of chronic GVHD occurring more than 6 months post-transplant would also constitute a risk factor. The role of TMP-SMX in the prevention of toxoplasmosis is still controversial. In our patient, however, TMP-SMX most probably prevented earlier reactivation of toxoplasmosis during the first 6 months after transplantation. Further studies of the efficacy of TMP-SMX in the prevention of toxoplasmosis will need to be done before this can be recommended as an alternative to the standard combination of pyrimethamine/sulphonamide or pyrimethamine/sulfadoxine (Fansidar) as reported by Foot et al. 8 
